

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	509	(546/123,514/300).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/25 08:47
L2	319	I1 and naphthyridine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/25 08:47
L3	18	I2 and phosphodiesterase	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/25 08:48

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds
NEWS EXPRESS	19 SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:49:56 ON 25 OCT 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:50:05 ON 25 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5

DICTIONARY FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10534582.str



chain nodes :
 17 18 19 20 21 22 23 24 25 27
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
 chain bonds :
 2-25 3-24 4-23 7-17 8-18 9-22 10-11 13-21 18-19 18-20 19-27
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
 14-15 15-16
 exact/norm bonds :
 5-7 6-10 7-8 7-17 8-9 9-10 10-11 13-21 18-19 18-20 19-27
 exact bonds :
 2-25 3-24 4-23 8-18 9-22
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
 isolated ring systems :
 containing 1 : 11 :

G1:H,Ak


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
 20:CLASS 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:50:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1164 TO 2276

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:50:27 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1888 TO ITERATE

100.0% PROCESSED 1888 ITERATIONS

171 ANSWERS

SEARCH TIME: 00.00.01

L3 171 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 08:50:32 ON 25 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Oct 2007 VOL 147 ISS 18
FILE LAST UPDATED: 24 Oct 2007 (20071024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 10 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:486169 CAPLUS

DOCUMENT NUMBER: 146:462241

TITLE: Process for the preparation of 1-aryl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide derivatives as phosphodiesterase-4 inhibitors

INVENTOR(S): Cameron, Mark; Hartner, Frederick W.; Tan, Lushi; Yasuda, Nobuyoshi; Yoshikawa, Naoki

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 59pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007050576	A2	20070503	WO 2006-US41424	20061024
WO 2007050576	A3	20070628		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-730596P P 20051027

OTHER SOURCE(S): CASREACT 146:462241

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a process for the preparation of a compound of structural formula I, which is a phosphodiesterase-4 inhibitor, and related derivs. The preparation of I can be illustrated by the following example. Coupling of 1-bromo-3-fluoro-4-iodobenzene with vinylmagnesium chloride in the presence of ZnCl₂ and a palladium catalyst gave 1-bromo-3-fluoro-4-vinylbenzene, which underwent stereoselective cyclopropanation with Et diazoacetate in the presence of copper triflate and a chiral bisoxazoline ligand to give cyclopropane II. Compound II was hydrolyzed with LiOH, recrystd. to sep. it from the cis-isomer, and esterified with ethanol and thionyl chloride to give pure trans-isomer II (99% ee). Boronic acid III was converted to the pinacol boronate ester with pinacol in toluene and this intermediate underwent amidation with cyclopropylamine, in the presence of MgCl₂, and acid hydrolysis to give boronic acid IV. Suzuki coupling of IV with II in DMF and n-propanol using Na₂CO₃ as a buffer, followed by ester hydrolysis with NaOH in methanol and deprotonation with NaOH gave sodium salt I.

IT 934995-86-5P 934995-87-6P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; process for preparation of aryl naphthyridinone carboxamide derivs. as phosphodiesterase-4 inhibitors)

RN 934995-86-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 934995-87-6 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 934995-88-7P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (target compound; process for preparation of aryl naphthyridinonecarboxamide
 derivs. as phosphodiesterase-4 inhibitors)
 RN 934995-88-7 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-
 1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodium salt
 (1:1), (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



● Na

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:484710 CAPLUS
 DOCUMENT NUMBER: 146:482049
 TITLE: A 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-
 naphthyridine-3-carboxamide phosphodiesterase-4-

inhibitor and a method of preparing it and its use in the treatment of asthma and inflammation

INVENTOR(S): Dube, Daniel; Gallant, Michel; Lacombe, Parick

PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.

SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007048225	A1	20070503	WO 2006-CA1729	20061023
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
US 2007099951	A1	20070503	US 2006-582697	20061018
PRIORITY APPLN. INFO.: GI			US 2005-730621P	P 20051027



AB The current application is directed to a compound of the structural formula I, crystal form and crystalline free acid thereof, pharmaceutical compns. comprising these compds. and methods of preparing same. These compds. are phosphodiesterase-4 inhibitors and are useful in the treatment of asthma and inflammation and are useful for the enhancement of cognition. Compound I was prepared by a multistep procedure (procedure given). The compound of the invention was evaluated for it's PDE-4 inhibitory activity.

IT 935674-06-9P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of oxo(phenyl)dihydronaphthyridinecarboxamide as phosphodiesterase-4 inhibitor and their use in the treatment of asthma,

inflammation, and enhancement of cognition)

RN 935674-06-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodium salt (1:1), (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 702639-63-2P 935674-10-5P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxo(phenyl)dihydronaphthyridinecarboxamide as phosphodiesterase-4 inhibitor and their use in the treatment of asthma, inflammation, and enhancement of cognition)

RN 702639-63-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 935674-10-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:59080 CAPLUS

DOCUMENT NUMBER: 144:318791

TITLE: Preparation and Solid-State Characterization of Nonstoichiometric Cocrystals of a Phosphodiesterase-IV Inhibitor and L-Tartaric Acid

AUTHOR(S): Variankaval, Narayan; Wenslow, Robert; Murry, Jerry; Hartman, Robert; Helmy, Roy; Kwong, Elizabeth; Clas,

CORPORATE SOURCE: Sophie-D.; Dalton, Chad; Santos, Ivan
Merck Research Laboratories, Merck & Co., Rahway, NJ,
07065, USA

SOURCE: Crystal Growth & Design (2006), 6(3), 690-700
CODEN: CGDEFU; ISSN: 1528-7483

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Evidence for a series of nonstoichiometric, isostructural, cocryst. complexes of L-883555, a phosphodiesterase-IV inhibitor, and L-tartaric acid with stoichiometries ranging from 0.3:1 to 0.9:1 is reported here. The free base form of this compound had insufficient bioavailability and, hence, could not be developed as a candidate for safety assessment studies. Several L-tartaric acid complexes were produced during an attempted salt-formation process, with the objective of increasing the bioavailability. It was found that the amount of L-tartaric acid incorporated in the cocryst. complexes could be controlled by adjusting the acid:base ratio in the reaction mixture without accompanying proton transfer between acid and base. Spectroscopic techniques were employed to locate the site of intermol. interaction between the acid and base as the N-oxide group in the base and the carboxylic acid of L-tartaric acid. Thermal and spectroscopic anal. of the degradation behavior for the various complexes showed the existence of at least two types of binding between the acid and base in those complexes with stoichiometries >0.5:1. The canonical hemitartrate complex was found to be more thermally stable than the other complexes, with acid:base stoichiometries lesser than or greater than 0.5:1 and was found to have much higher bioavailability than the free base in rhesus monkeys. This work shows the potential of designing suitable cocryst. complexes driven by favorable interactions between an acid and base in cases where conventional proton transfer does not occur to form a true salt, offering a route toward increased bioavailability in poorly absorbed compds.

IT 477252-51-0D, L 883555, complex with L-tartaric acid
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and solid-state characterization of nonstoichiometric cocrystals of a phosphodiesterase-IV inhibitor and L-tartaric acid)

RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:510348 CAPLUS


DOCUMENT NUMBER: 143:193927

TITLE: Practical application of new catalytic methods: a concise synthesis of a potent PDE IV inhibitor

AUTHOR(S): Albaneze-Walker, Jennifer; Murry, Jerry A.; Soheili, Arash; Ceglia, Scott; Springfield, Shawn A.; Bazaral, Charles; Dormer, Peter G.; Hughes, David L.
 CORPORATE SOURCE: Process Research, Merck Research Laboratories, Merck and Co., Inc., Rahway, NJ, 07065, USA
 SOURCE: Tetrahedron (2005), 61(26), 6330-6336
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:193927
 GI




AB An efficient synthesis of a potent PDE IV inhibitor I is described. The synthesis is highlighted by two practical and efficient catalytic reactions: a highly selective catalytic palladium mediated carbonylation of the pyridine side chain and an efficient palladium-catalyzed Suzuki-Miyaura coupling of a chloropyridine-N-oxide.
 IT 477252-51-0P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (scalable preparation of (cyclopropylcarbamoyl)(oxidopyridylphenyl)naphthyridine done as PDE IV inhibitor using regioselective carbonylation and Suzuki-Miyaura cross-coupling as key steps)
 RN 477252-51-0 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:1059128 CAPLUS
 DOCUMENT NUMBER: 142:32997
 TITLE: Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
 INVENTOR(S): Scolnick, Edward M.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105698	A2	20041209	WO 2004-US16492	20040525
WO 2004105698	A3	20050602		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633306	A2	20060315	EP 2004-753335	20040525
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006258668	A1	20061116	US 2005-557648	20051118
PRIORITY APPLN. INFO.:			US 2003-474168P	P 20030529
			WO 2004-US16492	W 20040525
AB				
The use of a phosphatase inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder. The phosphatase that is inhibited can be calcineurin or protein phosphatase 1. Treatment with a phosphatase inhibitor can be combined with a phosphodiesterase 4 inhibitor.				
IT				
701263-25-4P, N-Cyclopropyl-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,4-dihydro-1,8-naphthyridine-3-carboxamide 702640-57-1P 702640-64-0P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(intermediate; use of phosphatase inhibitors such calcineurin and protein phosphatase 1 as adjunct therapy for psychiatric disorders combined with phosphodiesterase 4 inhibitors)				
RN				
701263-25-4 CAPLUS				
CN				
1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)				



RN 702640-57-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-64-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 702639-56-3P, 2-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]-2-methylpropanoic acid
 702639-58-5P 702639-59-6P 702639-63-2P,
 2-trans-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid
 702639-69-8P, 2-trans-[3-Chloro-3'-[3-[(cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid 702639-71-2P, 2-cis-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid 702639-90-5P,
 (+)-trans-2-[3-Fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid 702639-91-6P 702639-93-8P, trans-2-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]-2-methylcyclopropanecarboxylic acid 702639-95-0P,
 2-trans-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid 702639-96-1P,
 3-Methyl-3-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]butanoic acid 702639-98-3P
 702640-04-8P, (+)-trans-2-[3-Chloro-3'-[3-[(cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid 702640-06-0P,
 (-)-trans-2-[3'-[4-Oxo-3-[[2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid 702640-13-9P, 3-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-(4H)-yl]biphenyl-4-yl]-2,2-dimethylpropanoic acid
 702640-28-6P, 4-[3'-[3-[(Cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-(4H)-yl]biphenyl-4-yl]-3,3-dimethylbutanoic acid
 702640-30-0P, 1-[[3'-[4-Oxo-3-[[2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]methyl]cyclobutanecarboxylic acid 702640-35-5P,
 2,2-Dimethyl-4-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]butanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of phosphatase inhibitors such calcineurin and protein phosphatase 1 as adjunct therapy for psychiatric disorders combined with phosphodiesterase 4 inhibitors)


RN 702639-56-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- β,β -dimethyl- (CA INDEX NAME)



RN 702639-58-5 CAPLUS


CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 702639-59-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-[1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-63-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-69-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-71-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-90-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702639-91-6 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 702639-93-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2-methyl-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-95-0 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702639-96-1 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[4-oxo-3-
[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (CA
INDEX NAME)



RN 702639-98-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-
trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-
yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-04-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-06-0 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




RN 702640-13-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl- (CA INDEX NAME)




RN 702640-28-6 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-β,β-dimethyl- (CA INDEX NAME)




RN 702640-30-0 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 702640-35-5 CAPLUS
 CN [1,1'-Biphenyl]-4-butanoic acid, α,α -dimethyl-3'-[4-oxo-3-
 [[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (CA
 INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:467891 CAPLUS
 DOCUMENT NUMBER: 141:38597
 TITLE: Preparation of aryl substituted 1,8-naphthyridin-4(1H)-
 ones as inhibitors of phosphodiesterase-4
 INVENTOR(S): Albaneze-Walker, Jennifer; Murry, Jerry Anthony;
 Soheili, Arash; Springfield, Shawn A.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048377	A2	20040610	WO 2003-US36806	20031118
WO 2004048377	A3	20040902		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2506656	A1	20040610	CA 2003-2506656	20031118
AU 2003291050	A1	20040618	AU 2003-291050	20031118
EP 1565466	A2	20050824	EP 2003-783636	20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016464	A	20051011	BR 2003-16464	20031118
CN 1738818	A	20060222	CN 2003-80108946	20031118
JP 2006513271	T	20060420	JP 2005-510366	20031118
US 2006019981	A1	20060126	US 2005-530465	20050405
MX 2005PA05405	A	20050803	MX 2005-PA5405	20050520
NO 2005003047	A	20050810	NO 2005-3047	20050621
PRIORITY APPLN. INFO.:			US 2002-428315P	P 20021122
			US 2003-472655P	P 20030522
			WO 2003-US36806	W 20031118
OTHER SOURCE(S):			MARPAT 141:38597	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB In one aspect, the present invention is directed to a one pot method of preparing intermediates I [OR1 = a suitable leaving group; R3 = (un)substituted alkyl, aryl, heteroaryl], which are useful in making inhibitors of phosphodiesterase-4. The present invention is also directed to a method of preparing phosphodiesterase inhibitors (no biol. data given) comprising the compds. II and III which comprises reacting IV [OR1 as above] with a 3-bromopyridine-N-oxide.HCl or 3-bromopyridine in the presence of a palladium catalyst and a phosphine ligand in amine base followed by reaction of the resulting V or VI with cyclopropylamine, optionally in the presence of catalyst. Thus, reacting IV [R1 = Et] with a 3-bromopyridine-N-oxide.HCl in the presence of [(allyl)PdCl]₂, P(tert-Bu)₃, tert-amylamine in DMAc followed by reacting V [R1 = Et] with cyclopropylamine afforded II. Preparation of 77 aryl substituted 1,8-naphthyridin-4(1H)-ones and their intermediates is also described.

IT 477251-83-5P 477251-87-9P 477251-92-6P
 477251-93-7P 477251-95-9P 477251-97-1P
 477251-99-3P 477252-00-9P 477252-01-0P
 477252-05-4P 477252-08-7P 477252-09-8P
 477252-11-2P 477252-23-6P 477252-25-8P
 477252-26-9P 477252-31-6P 477252-32-7P
 477252-36-1P 477252-43-0P 694489-52-6P
 701977-61-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aryl substituted 1,8-naphthyridin-4(1H)-ones as inhibitors of phosphodiesterase-4)


RN 477251-83-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-92-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (CA INDEX NAME)




RN 477251-95-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477251-99-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-00-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-05-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-08-7 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 477252-09-8 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-11-2 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-23-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-26-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-31-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-36-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 694489-52-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)



RN 701977-61-9 CAPLU
 CN [1,1'-Biphenyl]-3-4-oxo-1,8-naphthyridine



IT 477251-76-6P 47725
 477251-85-7P 47725
 477251-94-8P 47725
 477252-04-3P 47725
 477252-12-3P 47725
 477252-15-6P 47725
 477252-21-4P 47725
 477252-27-0P 47725
 477252-33-8P 47725
 477252-37-2P 47725
 477252-40-7P 47725
 477252-46-3P 47725
 477252-49-6P 47725
 477252-53-2P 47725
 477252-56-5P 47725
 477252-59-8P 47725
 477252-62-3P 47725
 477252-65-6P 69448
 701977-62-0P
 RL: PAC (Pharmacol
 (Therapeutic use);
 (Uses)


(preparation of
 of phosphodiester)
 RN 477251-76-6 CAPLU
 CN 1,8-Naphthyridine-
 dihydro-N-(1-methyl)

2-47-4P 477252-48-5P
2-50-9P 477252-51-0P
2-54-3P 477252-55-4P
2-57-6P 477252-58-7P
2-60-1P 477252-61-2P
2-63-4P 477252-64-5P
9-50-4P 694489-58-2P

ogical activity); SPN (Synthetic preparation); THU
BIOL (Biological study); PREP (Preparation); USES

aryl substituted 1,8-naphthyridin-4(1H)-ones as inhibitors
erase-4)


S
3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
lethyl)-4-oxo- (CA INDEX NAME)



S
carboxylic acid, 3'-[3-[[[(1-methylethyl)amino]carbonyl]-
idin-1(4H)-yl]-, ethyl ester (CA INDEX NAME)


-NHPr-i

1-82-4P 477251-84-6P
1-88-0P 477251-89-1P
2-02-1P 477252-03-2P
2-06-5P 477252-10-1P
2-13-4P 477252-14-5P
2-16-7P 477252-17-8P
2-22-5P 477252-24-7P
2-28-1P 477252-30-5P
2-34-9P 477252-35-0P
2-38-3P 477252-39-4P
2-41-8P 477252-44-1P




RN 477251-82-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-propyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-88-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-89-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 477252-02-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 477252-03-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-06-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-12-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-13-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-15-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-16-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-17-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-22-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-24-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-27-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-28-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-30-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-34-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methanolsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methanesulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-37-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethanesulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-38-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-39-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-41-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methylsulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-44-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (CA INDEX NAME)




RN 477252-47-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 477252-48-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



RN 477252-49-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-

methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-50-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-54-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-55-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-56-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-57-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinoliny)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-63-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-64-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-65-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 694489-50-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 694489-58-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)





RN 701977-62-0 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(1,6-dihydro-6-oxo-3-pyridinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:467889 CAPLUS
 DOCUMENT NUMBER: 141:38596
 TITLE: Preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors
 INVENTOR(S): Dube, Daniel; Gallant, Michel; Lacombe, Patrick; Aspiotis, Renee; Dube, Laurence; Girard, Yves; MacDonald, Dwight
 PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048374	A1	20040610	WO 2003-CA1800	20031119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2506648	A1	20040610	CA 2003-2506648	20031119
AU 2003283167	A1	20040618	AU 2003-283167	20031119
EP 1565464	A1	20050824	EP 2003-775029	20031119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016458	A	20051011	BR 2003-16458	20031119
CN 1738819	A	20060222	CN 2003-80108952	20031119
JP 2006508989	T	20060316	JP 2004-554102	20031119
US 2005107402	A1	20050519	US 2004-764229	20040123
US 7238706	B2	20070703		
ZA 2005003586	A	20060726	ZA 2005-3586	20050505
US 2006058316	A1	20060316	US 2005-534582	20050511
MX 2005PA05413	A	20050803	MX 2005-PA5413	20050520
NO 2005003046	A	20050727	NO 2005-3046	20050621
PRIORITY APPLN. INFO.:			US 2002-428611P	P 20021122
			WO 2003-CA1800	W 20031119
OTHER SOURCE(S):	MARPAT 141:38596			
GI				



AB Title compds. [I; Ar = Ph, pyridyl, pyrimidyl, indolyl, quinolyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl; Y = CO₂R₄, ACO₂R₄, etc.; A = alkyl; R, R₄ = H, alkyl; R₁ = H, (substituted) alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, heteroaryl, heterocyclyl; R₂ = H, halo, cyano, NO₂, (substituted) alkyl, cycloalkyl, alkoxy, Ph, heteroaryl, amino, etc.; R₃ = H, halo, cyano, NO₂, (substituted) alkyl, cycloalkyl, etc.], were prepared Thus, title compound (II) (preparation outlined) inhibited

PDE4-mediated hydrolysis of cAMP to AMP with IC₅₀ = 0.1 nM.

IT 702639-52-9P 702639-53-0P 702639-54-1P
 702639-55-2P 702639-56-3P 702639-57-4P
 702639-58-5P 702639-59-6P 702639-60-9P
 702639-61-0P 702639-62-1P 702639-63-2P
 702639-64-3P 702639-65-4P 702639-66-5P
 702639-67-6P 702639-69-8P 702639-71-2P
 702639-73-4P 702639-76-7P 702639-78-9P
 702639-80-3P 702639-81-4P 702639-83-6P
 702639-85-8P 702639-86-9P 702639-88-1P
 702639-90-5P 702639-91-6P 702639-93-8P
 702639-95-0P 702639-96-1P 702639-98-3P
 702640-00-4P 702640-02-6P 702640-04-8P
 702640-06-0P 702640-08-2P 702640-10-6P
 702640-12-8P 702640-13-9P 702640-15-1P
 702640-16-2P 702640-17-3P 702640-18-4P
 702640-19-5P 702640-20-8P 702640-21-9P

702640-22-0P 702640-23-1P 702640-24-2P
702640-25-3P 702640-26-4P 702640-27-5P
702640-28-6P 702640-29-7P 702640-30-0P
702640-31-1P 702640-32-2P 702640-33-3P
702640-34-4P 702640-35-5P 702640-36-6P
702640-37-7P 702640-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(claimed compound; preparation of biphenylnaphthyridonecarboxamides as
phosphodiesterase-4 inhibitors)

RN 702639-52-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-
1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 702639-53-0 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-
1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]-, (1R,2R)-rel- (CA INDEX
NAME)

Relative stereochemistry.




RN 702639-54-1 CAPLUS

CN [1,1'-Biphenyl]-3-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl- (CA INDEX NAME)




RN 702639-55-2 CAPLUS

CN [1,1'-Biphenyl]-4-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl- (CA INDEX NAME)




RN 702639-56-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-β,β-dimethyl- (CA INDEX NAME)




RN 702639-57-4 CAPLUS

CN [1,1'-Biphenyl]-4-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α-hydroxy- (CA INDEX NAME)



RN 702639-58-5 CAPLUS


CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 702639-59-6 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 702639-60-9 CAPLUS

CN 1,3-Dioxolane-4-carboxylic acid, 5-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl- (CA INDEX NAME)




RN 702639-61-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 702639-62-1 CAPLUS


CN Cyclopropanecarboxylic acid, 1-cyano-3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl- (CA INDEX NAME)



RN 702639-63-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-64-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-65-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-bromo-5'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-66-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-methyl[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-67-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-2-methyl[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-69-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-71-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702639-73-4 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- (CA INDEX NAME)



RN 702639-76-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-78-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methylthio)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-80-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methanesulfonyl)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-81-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-83-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[5-[3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-2-thienyl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-85-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(cyclopropylmethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-86-9 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(1-cyanocyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702639-88-1 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- (CA INDEX NAME)



RN 702639-90-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702639-91-6 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 702639-93-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2-methyl-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702639-95-0 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702639-96-1 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (CA INDEX NAME)



RN 702639-98-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-00-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[(2,2,3,3,3-pentafluoropropyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-02-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-1-fluoro-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-04-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-06-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 702640-08-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-10-6 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1-methylethyl ester, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 702640-12-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 702640-13-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 702640-15-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 702640-16-2 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 702640-17-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl- (CA INDEX NAME)



RN 702640-18-4 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)



RN 702640-19-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(1,1-dimethylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-20-8 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclobutylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 702640-21-9 CAPLUS

CN Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 702640-22-0 CAPLUS


CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-γ-hydroxy-γ-methyl- (CA INDEX NAME)



RN 702640-23-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-24-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(dicyclopropylmethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-25-3 CAPLUS


CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (CA INDEX NAME)



RN 702640-26-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(1-hydroxycyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-27-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[1-phenylcyclopropyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-28-6 CAPLUS


CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-β,β-dimethyl- (CA INDEX NAME)



RN 702640-29-7 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[1-cyclopropyl-1-methylethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-30-0 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 702640-31-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[cyclopropylmethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-32-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[3-[[1-hydroxycyclopropyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 702640-33-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoro-1-methylethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-34-4 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[1-methylcyclopropyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 702640-35-5 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, α,α -dimethyl-3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (CA INDEX NAME)



RN 702640-36-6 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, α,α -dimethyl-3'-[4-oxo-3-
[[(2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]- (CA
INDEX NAME)



RN 702640-37-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-
[(cyclopropylamino) carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-
biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 702640-38-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 702640-46-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors)

RN 702640-46-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 701263-25-4 702640-57-1 702640-59-3

702640-62-8 702640-64-0 702640-66-2

702640-70-8 702640-74-2 702640-76-4


702640-77-5 702640-79-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors)

RN 701263-25-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)



RN 702640-57-1 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 702640-59-3 CAPLUS

CN 1,3-Dioxolane-4-carboxylic acid, 5-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl-, ethyl ester (CA INDEX NAME)



RN 702640-62-8 CAPLUS


CN Cyclopropanecarboxylic acid, 1-cyano-3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 702640-64-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 702640-66-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-bromo-5'-[3-
[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-
biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702640-70-8 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-
oxo-1,8-naphthyridin-1(4H)-yl]-, ethyl ester (CA INDEX NAME)



RN 702640-74-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methylthio)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 702640-76-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)



RN 702640-77-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-79-7 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:467741 CAPLUS

DOCUMENT NUMBER: 141:38595

TITLE: Preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as enhancers of cognition

INVENTOR(S): Dube, Daniel; Gallant, Michel; Lacombe, Patrick; Girard, Yves; MacDonald, Dwight; Friesen, Richard; Ducharme, Yves; Cote, Bernard; Blouin, Marc; Martins, Evelyn; Guay, Daniel; Girard, Mario; Frenette, Richard; Laliberte, Sebastien; Robichaud, Annette; Mastracchio, Anthony; Perrier, Helene

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.; Hamel, Pierre

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047836	A1	20040610	WO 2003-CA1799	20031119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TŽ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003286024	A1	20040618	AU 2003-286024	20031119
EP 1592419	A1	20051109	EP 2003-776698	20031119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006040981	A1	20060223	US 2005-536250	20050520
PRIORITY APPLN. INFO.:			US 2002-428541P	P 20021122
			WO 2003-CA1799	W 20031119

GI



AB Substituted naphthyridines are prepared as PDE-4 inhibitors. For instance, Et 3-(3-bromoanilino)-2-(2-chloronicotinoyl)acrylate (preparation given) is treated with NaH in THF to give Et 1-(3-bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxylate. This intermediate is saponified, coupled to i-PrNH₂ (THF, Et₃N, i-BuOCOC₂H₅) and coupled to 3-acetylphenylboronic acid (PhMe, EtOH, Na₂CO₃, trans-dibromobis(triphenylphosphine)palladium, reflux, 1 h) to give I. Example compds. have IC₅₀ values of 0.1 to 90.0 nM for PDE4; these compds. are useful for enhancing memory, learning, retention, recall, awareness and judgement.

IT 477251-83-5P, N-Isopropyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-87-9P, N-Isopropyl-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-91-5P, N-(2,6-Dichloropyridin-4-yl)-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-92-6P 477251-93-7P, N-Isopropyl-1-[3-(quinolin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-95-9P, N-Cyclopropyl-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-97-1P,


N-Isopropyl-1-[3-[5-(methylsulfanyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-99-3P,
 N-Cyclopropyl-1-[3-(4-hydroxymethylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-00-9P,
 N-Cyclopropyl-1-[3-(pyridin-4-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-01-0P, N-Cyclopropyl-1-[3-[4-(ethylsulfanyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-05-4P, N-Isopropyl-1-[3-[4-(methylsulfanyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-07-6P, N-Isopropyl-1-[3-(5-carboethoxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-08-7P, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-09-8P, N-Isopropyl-1-[3-[6-(2-methylpropyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-10-1P 477252-11-2P, N-Isopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-23-6P, N-Cyclopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-25-8P, N-Cyclopropyl-1-[3-(5-bromopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-26-9P, N-Cyclopropyl-1-[3-(6-benzoyloxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-31-6P, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-32-7P, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-35-0P, N-Cyclopropyl-1-[3-(6-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-43-0P, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as enhancers of cognition)


RN 477251-83-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-91-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-92-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (CA INDEX NAME)




RN 477251-95-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477251-99-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-00-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-05-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-07-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[1-methylethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester (CA INDEX NAME)




RN 477252-08-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-09-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-11-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-23-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-26-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-31-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)



IT 477251-76-6P, N-Isopropyl-1-[3-(3-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-80-2P, N-(2,6-Dichloropyridin-4-yl)-1-[3-(3-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-82-4P 477251-84-6P, N-Isopropyl-1-[3-(2-methylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-85-7P, N-Isopropyl-N-methyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-88-0P, N-Isopropyl-1-[3-(indol-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-89-1P, N-tert-Butyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477251-94-8P, N-Isopropyl-1-[3-(pyrimidin-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-02-1P, N-Cyclopropyl-1-[3-(3-thienyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-03-2P, N-Cyclopropyl-1-[3-(4-sulfamoylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-04-3P, N-Isopropyl-1-[3-(3-ethoxyphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-06-5P, N-Isopropyl-1-[3-(3-acetyl-4-hydroxyphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-12-3P, N-Cyclopropyl-1-[3-(1-oxidopyrimidin-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-13-4P, 1-[3-[6-(1-Hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-14-5P 477252-15-6P, N-Cyclopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-16-7P, N-Cyclopropyl-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-17-8P, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-18-9P, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)pyridin-4-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-19-0P, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxidopyridin-4-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-21-4P, N-Cyclopropyl-1-[3-(6-isopropylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-22-5P, N-Cyclopropyl-1-[3-(6-methoxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-24-7P, N-Cyclopropyl-1-[3-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide


477252-27-0P, N-Cyclopropyl-1-[3-[6-(bis(cyclopropyl)(hydroxy)methyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-28-1P, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-30-5P, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-33-8P, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-34-9P 477252-36-1P, N-Isopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-37-2P, N-Cyclopropyl-1-[3-[4-(ethylsulfonyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-38-3P, N-Cyclopropyl-1-[3-[4-(ethylsulfinyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-39-4P 477252-40-7P 477252-41-8P, N-Cyclopropyl-1-[3-[4-[(methylsulfonyl)methyl]phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-42-9P, N-Cyclopropyl-1-[3-(1,6-dihydro-6-oxopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-44-1P, N-Isopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-45-2P, N-(2,6-Dichloropyridin-4-yl)-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-46-3P, N-Isopropyl-1-[3-(5-carboethoxy-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-47-4P, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-48-5P, N-Isopropyl-1-[3-[6-(2-methylpropyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-49-6P, N-Isopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-50-9P, N-Cyclopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-51-0P, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-53-2P, N-Cyclopropyl-1-[3-(1-oxidopyridin-4-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-54-3P, N-Cyclopropyl-1-[3-(5-bromo-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-55-4P, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-57-6P, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-58-7P, N-Isopropyl-1-[3-(1-oxidoquinolin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-59-8P, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-60-1P, N-Cyclopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-61-2P, N-Cyclopropyl-1-[3-(6-methylsulfonyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-62-3P, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 477252-63-4P, N-Cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as enhancers of cognition)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-80-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-82-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-propyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-88-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-89-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 477252-02-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 477252-03-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-06-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-12-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-13-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-15-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-16-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-17-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-18-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-19-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-22-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-24-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-27-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-28-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-30-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-34-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-36-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-37-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-38-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-39-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-41-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methylsulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-42-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(1,6-dihydro-6-oxo-3-pyridinyl)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-44-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-45-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[1-(methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (CA INDEX NAME)




RN 477252-47-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-48-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-50-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-54-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-55-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-57-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)



RN 477252-63-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:433770 CAPLUS

DOCUMENT NUMBER: 141:7041

TITLE: One-pot preparation of naphthyridine derivatives, useful as inhibitors of phosphodiesterase-4

INVENTOR(S): Albaneze-Walker, Jennifer; Ceglia, Scott; Murry, Jerry Anthony; Soheili, Arash

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 57 pp., which
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102472	A1	20040527	US 2003-690118	20031021
US 6909002	B2	20050621		
PRIORITY APPLN. INFO.:			US 2002-428315P	P 20021122
			US 2003-472598P	P 20030522
OTHER SOURCE(S):			CASREACT 141:7041; MARPAT 141:7041	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to one-pot preparation of naphthyridine derivs. of formula I [wherein: OR1 is a suitable leaving group; R2 is C1-8alkyl, (un)substituted (hetero)aryl], useful as inhibitors of phosphodiesterase-4 (no biol. data). For instance, naphthyridine derivative II was prepared via heterocyclization of Et 2-chloronicotinoylacetate, 3-bromoaniline, and acetic anhydride, hydrolysis of the obtained ester III (R3 = Br), amidation by isopropylamine, and subsequent phenylacetylation by 3-acetylphenylboronic acid (example 1, no yield data). Naphthyridine derivative IV was prepared using the prepared intermediate III [R3 = -B(OH)2]

(p.

49-53).


IT 477252-05-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors of phosphodiesterase-4)

RN 477252-05-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)



IT 477251-76-6P 477251-82-4P 477251-83-5P
 477251-84-6P 477251-85-7P 477251-87-9P
 477251-88-0P 477251-89-1P 477251-92-6P
 477251-93-7P 477251-94-8P 477251-95-9P
 477251-97-1P 477251-99-3P 477252-00-9P
 477252-01-0P 477252-02-1P 477252-03-2P
 477252-04-3P 477252-06-5P 477252-07-6P
 477252-08-7P 477252-09-8P 477252-10-1P


477252-11-2P 477252-13-4P 477252-14-5P
 477252-15-6P 477252-16-7P 477252-21-4P
 477252-22-5P 477252-23-6P 477252-24-7P
 477252-25-8P 477252-26-9P 477252-27-0P
 477252-28-1P 477252-30-5P 477252-31-6P
 477252-32-7P 477252-33-8P 477252-34-9P
 477252-35-0P 477252-36-1P 477252-39-4P
 477252-40-7P 477252-41-8P 477252-43-0P
 477252-64-5P 477252-65-6P 694489-50-4P
 694489-52-6P 694489-53-7P 694489-54-8P
 694489-55-9P 694489-56-0P 694489-57-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors of phosphodiesterase-4)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-82-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-propyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 477251-83-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-88-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-89-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-92-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (CA INDEX NAME)




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 477251-95-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477251-99-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-00-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-02-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 477252-03-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-06-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-07-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester (CA INDEX NAME)




RN 477252-08-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-09-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-11-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-13-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-15-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-16-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-22-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-23-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-24-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-26-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-27-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-28-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-30-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-31-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-34-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-36-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME).




RN 477252-39-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-41-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methylsulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-64-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-65-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 694489-50-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 694489-52-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 694489-53-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 694489-54-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 694489-55-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 694489-56-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 694489-57-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3'-(1,6-dihydro-6-oxo-3-pyridinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




IT 701263-25-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors of phosphodiesterase-4)

RN 701263-25-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)




IT 477252-46-3P 477252-47-4P 477252-48-5P
 477252-49-6P 477252-50-9P 477252-51-0P
 477252-53-2P 477252-54-3P 477252-55-4P
 477252-56-5P 477252-57-6P 477252-58-7P
 477252-59-8P 477252-60-1P 477252-61-2P
 477252-62-3P 477252-63-4P 694489-58-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(one-pot preparation of naphthyridine derivs., useful as inhibitors of phosphodiesterase-4)


RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[1-(methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (CA INDEX NAME)




RN 477252-47-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-48-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-50-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-54-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-55-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-56-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-57-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-63-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)



RN 694489-58-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:906219 CAPLUS

DOCUMENT NUMBER: 138:4594

TITLE: Preparation of 1-biaryl-[1,8]naphthyridin-4-one phosphodiesterase IV inhibitors for treatment of asthma and inflammation

INVENTOR(S): Guay, Daniel; Girard, Mario; Hamel, Pierre; Laliberte, Sebastien; Friesen, Richard; Girard, Yves; Li, Chun

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.

SOURCE: PCT Int. Appl., 166 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094823	A1	20021128	WO 2002-CA746	20020522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2447765	A1	20021128	CA 2002-2447765	20020522
AU 2002257459	A1	20021203	AU 2002-257459	20020522
EP 1397359	A1	20040317	EP 2002-727127	20020522
EP 1397359	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534773	T	20041118	JP 2002-591496	20020522
AT 303384	T	20050915	AT 2002-727127	20020522
ES 2247325	T3	20060301	ES 2002-2727127	20020522
US 2003096829	A1	20030522	US 2002-154591	20020524
US 6677351	B2	20040113		
PRIORITY APPLN. INFO.:			US 2001-293247P	P 20010524
			WO 2002-CA746	W 20020522
OTHER SOURCE(S):			MARPAT 138:4594	
GI				




- AB Title compds. I [wherein Ar = Ph, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, or heteroaryl oxides; R = H or alkyl; R1 = H or (un)substituted (cyclo)alkyl, alkoxy, alkenyl, alkynyl, heteroaryl, or heterocyclyl; R2 = H, halo, (cyclo)alkyl, alkoxy, amino, acyl, alkoxycarbonyl, alkylsulfamoyl, alkylsulfonyl, or (un)substituted Ph, heteroaryl, or heterocyclyl, etc.; R3 = H, OH, NH2, halo, (un)substituted alkyl; R4-R7 = independently H, halo, NH2, or (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salts thereof] were prepared as phosphodiesterase IV (PDE4) inhibitors for the treatment of asthma and inflammation. For instance, Et 3-(3-bromoanilino)-2-(2-chloronicotinoyl)acrylate was cyclized using NaH in THF and the resulting ester saponified to give 1-(3-bromophenyl)-1,4-dihydro-[1,8]naphthyridin-4-one-3-carboxylic acid. Amidation with isopropylamine, followed by treatment with 3-acetylphenylboronic acid in the presence of trans-PdBr₂(PPh₃)₂ and Na₂CO₃ in toluene and EtOH gave II. I demonstrated PDE4 inhibitory activity by suppression of TNF- α secretion in LPS stimulated human blood with IC₅₀ values generally ranging from 0.005 μ M to 15.4 μ M. In a SPA based PDE activity assay, I inhibited the hydrolysis of cAMP to AMP by human recombinant phosphodiesterase IVa with IC₅₀ values between 34.3 nM and 134.0 nM.
- IT 477251-83-5P, N-Isopropyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-87-9P, N-Isopropyl-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-91-5P, N-(2,6-Dichloropyridin-4-yl)-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-92-6P, N-Isopropyl-1-[3-[4-(4-(tert-butyloxycarbonyl)piperazin-1-yl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-93-7P, N-Isopropyl-1-[3-(quinolin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-95-9P, N-Cyclopropyl-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-97-1P, N-Isopropyl-1-[3-(5-methylthiopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-99-3P, N-Cyclopropyl-1-[3-(4-hydroxymethylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-00-9P, N-Cyclopropyl-1-[3-(pyridin-4-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-01-0P, N-Cyclopropyl-1-[3-(4-ethylthiophenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-05-4P, N-Isopropyl-1-[3-(4-methylthiophenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-07-6P, N-Isopropyl-1-[3-(5-carboethoxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-08-7P, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-09-8P, N-Isopropyl-1-[3-[6-(2-methylpropyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-

[1,8]naphthyridine-3-carboxamide 477252-11-2P,
 N-Isopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-23-6P,
 N-Cyclopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-25-8P,
 N-Cyclopropyl-1-[3-(5-bromopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-26-9P,
 N-Cyclopropyl-1-[3-(6-benzyloxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-31-6P,
 N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-32-7P,
 N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)pyridin-3-
 yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-35-0P, N-Cyclopropyl-1-[3-(6-methylsulfonylpyridin-3-
 yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-43-0P, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-
 methylethyl)pyridin-3-yl]pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4 inhibitor; preparation of biaryl naphthyridinone PDE4 inhibitors by
 cyclization and arylation of (arylamino)(nicotinoyl)acrylates for
 treatment of asthma and inflammation)


RN 477251-83-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
 dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-
 (3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-91-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-
 4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-92-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[{(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (CA INDEX NAME)




RN 477251-95-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477251-99-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-00-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-05-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-07-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl-, ethyl ester (CA INDEX NAME)




RN 477252-08-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-09-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-11-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-23-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-26-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 477252-31-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methysulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)



IT 477251-76-6P, N-Isopropyl-1-[3-(3-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-80-2P, N-(2,6-Dichloropyridin-4-yl)-1-[3-(3-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-82-4P, N-Isopropyl-1-[3-(4-n-propylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-84-6P, N-Isopropyl-1-[3-(2-methylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-85-7P, N-Isopropyl-N-methyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-88-0P, N-Isopropyl-1-[3-(indol-5-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-89-1P, N-tert-Butyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477251-94-8P, N-Isopropyl-1-[3-(pyrimidin-5-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-02-1P, N-Cyclopropyl-1-[3-(3-thienyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-03-2P, N-Cyclopropyl-1-[3-(4-sulfamoylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-04-3P, N-Isopropyl-1-[3-(3-ethoxyphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-06-5P, N-Isopropyl-1-[3-(3-acetyl-4-hydroxyphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-10-1P,

N-Isopropyl-1-[3-(5-acetylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-12-3P,
 N-Cyclopropyl-1-[3-(1-oxidopyrimidin-5-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-13-4P,
 1-[3-[6-(1-Hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-14-5P,
 N-Isopropyl-1-[3-[4-(pyridin-3-yl)phenyl]phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-15-6P,
 N-Cyclopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-16-7P,
 N-Cyclopropyl-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-
 yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-17-8P, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-
 methylethyl)pyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-18-9P, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-
 methylethyl)pyridin-4-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-19-0P, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-
 methylethyl)-1-oxidopyridin-4-yl]phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-21-4P,
 N-Cyclopropyl-1-[3-(6-isopropylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-22-5P,
 N-Cyclopropyl-1-[3-(6-methoxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-24-7P,
 N-Cyclopropyl-1-[3-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl]-4-oxo-
 1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-27-0P,
 N-Cyclopropyl-1-[3-[6-dicyclopropyl(hydroxy)methyl-1-oxidopyridin-3-
 yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-28-1P, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-
 oxidopyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-30-5P, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-
 methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-33-8P, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-
 methylethyl)pyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-34-9P, N-Isopropyl-1-[3-(4-
 methylsulfonylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-36-1P, N-Isopropyl-1-[3-(5-
 methylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-37-2P, N-Cyclopropyl-1-[3-(4-
 ethylsulfonylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-38-3P, N-Cyclopropyl-1-[3-(4-
 ethylsulfinylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-39-4P, N-Isopropyl-1-[3-[4-(1-
 oximidoethyl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-
 carboxamide 477252-40-7P, N-Isopropyl-1-[3-[4-(piperazin-1-
 yl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-41-8P, N-Cyclopropyl-1-[3-[4-(methylsulfonylmethyl)phenyl]p
 henyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-42-9P, N-Cyclopropyl-1-[3-(1,6-dihydro-6-oxopyridin-3-
 yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 477252-44-1P, N-Isopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-
 1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-45-2P,
 N-(2,6-Dichloropyridin-4-yl)-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-46-3P,
 N-Isopropyl-1-[3-(5-carboethoxy-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-47-4P,
 N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-
 4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-48-5P,
 N-Isopropyl-1-[3-[6-(2-methylpropyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-
 dihydro-[1,8]naphthyridine-3-carboxamide 477252-49-6P,
 N-Isopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-50-9P,
 N-Cyclopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-
 [1,8]naphthyridine-3-carboxamide 477252-51-0P,


N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-53-2P, N-Cyclopropyl-1-[3-(1-oxidopyridin-4-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-54-3P, N-Cyclopropyl-1-[3-(5-bromo-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-55-4P, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]pyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-56-5P, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-57-6P, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-58-7P, N-Isopropyl-1-[3-(1-oxidoquinolin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-59-8P, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-60-1P, N-Cyclopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-61-2P, N-Cyclopropyl-1-[3-(6-methylsulfonyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-62-3P, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-63-4P, N-Cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide 477252-64-5P 477252-65-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of biaryl naphthyridinone PDE4 inhibitors by cyclization and arylation of (arylamino)(nicotinoyl)acrylates for treatment of asthma and inflammation)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-80-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-82-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-propyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-88-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477251-89-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 477252-02-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 477252-03-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-06-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-12-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-13-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-15-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-16-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-17-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-18-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-19-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-22-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-24-7 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (CA INDEX NAME)



RN 477252-27-0 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopentylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-28-1 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-30-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-34-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-36-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-37-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-38-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-39-4 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 477252-40-7 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 477252-41-8 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(methanesulfonylmethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (CA INDEX NAME)




RN 477252-42-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(1,6-dihydro-6-oxo-3-pyridinyl)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-44-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-45-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (CA INDEX NAME)




RN 477252-47-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 477252-48-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-50-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-54-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-55-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-{6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl}phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-56-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-57-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-63-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 477252-64-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



RN 477252-65-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his